89bio Inc (ETNB) is a clinical-stage biopharmaceutical company that is focused on developing innovative therapies for liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is a glycoPEGylated analog of fibroblast growth factor 21 (FGF21), which is a hormone that regulates metabolic processes in the body. BIO89-100 is currently in Phase 2 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), a chronic liver disease characterized by the buildup of fat in the liver, inflammation, and liver damage. 89bio is also exploring the potential of BIO89-100 for other indications, such as severe hypertriglyceridemia and type 2 diabetes.
89bio Inc (ETNB) is a clinical-stage biopharmaceutical company that is focused on developing innovative therapies for liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is a glycoPEGylated analog of fibroblast growth factor 21 (FGF21), which is a hormone that regulates metabolic processes in the body. BIO89-100 is currently in Phase 2 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), a chronic liver disease characterized by the buildup of fat in the liver, inflammation, and liver damage. 89bio is also exploring the potential of BIO89-100 for other indications, such as severe hypertriglyceridemia and type 2 diabetes.